JP2020536531A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020536531A5 JP2020536531A5 JP2020518645A JP2020518645A JP2020536531A5 JP 2020536531 A5 JP2020536531 A5 JP 2020536531A5 JP 2020518645 A JP2020518645 A JP 2020518645A JP 2020518645 A JP2020518645 A JP 2020518645A JP 2020536531 A5 JP2020536531 A5 JP 2020536531A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- domain
- car
- cancer
- cell death
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 15
- 229920001184 polypeptide Polymers 0.000 claims 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims 11
- 108090000765 processed proteins & peptides Proteins 0.000 claims 11
- 230000001086 cytosolic effect Effects 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 238000003782 apoptosis assay Methods 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 4
- 230000005522 programmed cell death Effects 0.000 claims 4
- 230000011664 signaling Effects 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 108091007744 Programmed cell death receptors Proteins 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000000973 chemotherapeutic effect Effects 0.000 claims 2
- 230000003439 radiotherapeutic effect Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 claims 1
- 101150090209 HCST gene Proteins 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762563336P | 2017-09-26 | 2017-09-26 | |
| US62/563,336 | 2017-09-26 | ||
| PCT/US2018/052799 WO2019067504A1 (en) | 2017-09-26 | 2018-09-26 | SPECIFIC CHIMERIC ANTIGEN RECEPTOR AT PD-1 AS IMMUNOTHERAPY |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020536531A JP2020536531A (ja) | 2020-12-17 |
| JP2020536531A5 true JP2020536531A5 (enExample) | 2021-09-30 |
Family
ID=65903543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020518645A Pending JP2020536531A (ja) | 2017-09-26 | 2018-09-26 | 免疫療法としてのｐｄ１特異的キメラ抗原受容体 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11559549B2 (enExample) |
| EP (1) | EP3688143A4 (enExample) |
| JP (1) | JP2020536531A (enExample) |
| KR (1) | KR20200070236A (enExample) |
| CN (1) | CN111433354A (enExample) |
| AU (1) | AU2018339528A1 (enExample) |
| CA (1) | CA3077187A1 (enExample) |
| MX (1) | MX2020007357A (enExample) |
| WO (1) | WO2019067504A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016281641B2 (en) * | 2015-06-23 | 2022-01-20 | Eureka Therapeutics, Inc. | Novel PD-1 immune modulating agents |
| MX2020007357A (es) | 2017-09-26 | 2021-08-11 | Longwood Univ | Reporte de antígeno quimérico específico de pd1 como una inmunoterapia. |
| KR20230010228A (ko) * | 2020-05-08 | 2023-01-18 | 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 | 자연 살해 세포를 표적으로 하는 키메라 항원 수용체 (cars) |
| WO2022211376A1 (ko) * | 2021-04-01 | 2022-10-06 | 주식회사 이뮤노로지컬디자이닝랩 | 키메릭 항원 수용체(car)를 포함하는 형질전환된 항원 특이적 전문적 항원표출세포 및 이의 용도 |
| KR20220144000A (ko) * | 2021-04-16 | 2022-10-26 | 주식회사 이뮤노로지컬디자이닝랩 | Programmed death-ligand 1(PD-L1)에 특이적으로 결합하는 키메릭 항원 수용체 및 이의 용도 |
| WO2023107511A2 (en) * | 2021-12-06 | 2023-06-15 | Vycellix, Inc. | Chimeric switch receptors in NK cells |
| KR20250034432A (ko) | 2022-07-05 | 2025-03-11 | 네오믹스 파마슈티컬즈 엘엘씨 | 키메라 세포내 신호전달 도메인에 연결된 bcma 나노바디를 포함하는 키메라 항원 수용체 |
| CN118359727A (zh) * | 2023-01-17 | 2024-07-19 | 上海以慈生物科技有限公司 | 突变的pd1胞外域片段及含有该片段的car和nk细胞 |
| WO2025059162A1 (en) | 2023-09-11 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Car-engager containing il-2 variants to enhance the functionality of car t cells |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12013501201A1 (en) * | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| ES2888651T3 (es) * | 2011-07-29 | 2022-01-05 | Univ Pennsylvania | Receptores de conmutación coestimulantes |
| US10611837B2 (en) * | 2014-04-10 | 2020-04-07 | Seattle Children's Hospital | Transgene genetic tags and methods of use |
| EP3151672B1 (en) * | 2014-06-06 | 2020-11-04 | Bluebird Bio, Inc. | Improved t cell compositions |
| AU2015305531B2 (en) | 2014-08-19 | 2021-05-20 | Novartis Ag | Anti-CD123 chimeric antigen receptor (CAR) for use in cancer treatment |
| BR112017008710A8 (pt) * | 2014-10-27 | 2023-04-25 | Hutchinson Fred Cancer Res | Composições e métodos para estimular a eficácia de imunoterapia celular adotiva |
| EP3549612B1 (en) * | 2015-03-02 | 2025-04-30 | Innovative Cellular Therapeutics Holdings, Ltd. | Reducing immune tolerance induced by pd-l1 |
| CN106350533B (zh) * | 2015-10-09 | 2020-07-17 | 上海宇研生物技术有限公司 | Anti-PD-L1-CAR-T及其制备方法和应用 |
| KR20250089563A (ko) | 2015-10-20 | 2025-06-18 | 카이트 파마 인코포레이티드 | T 세포 요법을 위한 t 세포를 제조하는 방법 |
| CN106399255B (zh) * | 2016-04-13 | 2019-10-18 | 阿思科力(苏州)生物科技有限公司 | Pd-1 car-t细胞及其制备方法和应用 |
| WO2018170021A1 (en) | 2017-03-16 | 2018-09-20 | Alpine Immune Sciences, Inc. | Pd-l1 variant immunomodulatory proteins and uses thereof |
| MX2020007357A (es) | 2017-09-26 | 2021-08-11 | Longwood Univ | Reporte de antígeno quimérico específico de pd1 como una inmunoterapia. |
| CN108384795A (zh) | 2017-10-13 | 2018-08-10 | 江苏西迪尔生物技术有限公司 | 作用于tme免疫效应细胞的人工合成基因及验证方法和应用 |
-
2018
- 2018-09-26 MX MX2020007357A patent/MX2020007357A/es unknown
- 2018-09-26 KR KR1020207009640A patent/KR20200070236A/ko not_active Ceased
- 2018-09-26 CA CA3077187A patent/CA3077187A1/en active Pending
- 2018-09-26 EP EP18862531.3A patent/EP3688143A4/en not_active Withdrawn
- 2018-09-26 WO PCT/US2018/052799 patent/WO2019067504A1/en not_active Ceased
- 2018-09-26 AU AU2018339528A patent/AU2018339528A1/en not_active Abandoned
- 2018-09-26 CN CN201880075793.XA patent/CN111433354A/zh active Pending
- 2018-09-26 US US16/650,884 patent/US11559549B2/en active Active
- 2018-09-26 JP JP2020518645A patent/JP2020536531A/ja active Pending
-
2022
- 2022-12-29 US US18/147,879 patent/US20230293583A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020536531A5 (enExample) | ||
| Kamiya et al. | Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells | |
| US20240059754A1 (en) | Chimeric antigen receptors and enhancement of anti-tumor activity | |
| Payne et al. | BTN3A1 governs antitumor responses by coordinating αβ and γδ T cells | |
| Pockley et al. | NK cell-based therapeutics for lung cancer | |
| Bi et al. | NK cell exhaustion | |
| Ye et al. | Engineering chimeric antigen receptor-T cells for cancer treatment | |
| Azuma et al. | Requirements for CD28-dependent T cell-mediated cytotoxicity | |
| Blank et al. | Blockade of PD‐L1 (B7‐H1) augments human tumor‐specific T cell responses in vitro | |
| JP2020505932A5 (enExample) | ||
| JP2018504143A5 (enExample) | ||
| Schleypen et al. | Renal cell carcinoma‐infiltrating natural killer cells express differential repertoires of activating and inhibitory receptors and are inhibited by specific HLA class I allotypes | |
| JP2018504145A5 (enExample) | ||
| JP2023116720A (ja) | 細胞療法と免疫調節化合物の併用 | |
| JP2018029594A5 (enExample) | ||
| RU2015117237A (ru) | Химерные антигенные рецепторы м971 | |
| JP2020511136A5 (enExample) | ||
| Tsirigotis et al. | Programmed death-1 immune checkpoint blockade in the treatment of hematological malignancies | |
| Fujiki et al. | Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1* 0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes | |
| CN113474450A (zh) | 产生工程化细胞的方法以及所述工程化细胞的组合物 | |
| CN110621335A (zh) | 免疫调节融合蛋白及其用途 | |
| JP2018508219A5 (enExample) | ||
| JP2016502512A5 (enExample) | ||
| JP2017515464A5 (enExample) | ||
| Saibil et al. | Targeting T cell activation in immuno-oncology |